1. 1.World Health Organization. Globalnaja strategija sektora zdravoohranenija po virusnomu gepatitu 2016-2021 na puti k likvidacii virusnogo gepatita [Internet]. Available from: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/ru/. (Russian).
2. 2.Mikhaylov MI, Yushchuk ND, Malinnikova EYu, Kyuregyan KK, Isaeva OV, Znoyko OO, Klimova EA. Proekt programmy po kontrolju i likvidacii virusnyh gepatitov kak problemy obshhestvennogo zdorovja v Rossijskoj Federacii [The design of the program for control and elimination of viral hepatitis as public health problem in the Russian Federation]. Infekcionnye bolezni: novosti, mnenija, obuchenie [Infectious diseases: news, views, education]. 2018;7(2):52-58. https://doi.org/10.24411/2305-3496-2018-12005. (Russian).
3. 3.Polyanina AV, Bystrova TN. Molekuljarno- jepidemiologicheskaja harakteristika virusa gepatita B v uslovijah massovoj vakcinoprofilaktiki [Molecular and epidemiological characteristics of hepatitis B virus in conditions of mass vaccine prophylaxis]. Zhurnal MediAl [Journal MediAl]. 2019;24(2):10-39. https://doi.org/10.21145/2225-0026-2019-2-10-39. (Russian).
4. 4.Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33(2):e00046-19. https://doi.org/10.1128/CMR.00046-19.
5. 5.Zampino R, Sagnelli C, Boemio A, Sagnelli E, Coppola N. Treatment of chronic HBV infection in developing countries. Ann Hepatol. 2016;15(6):816-823. https://doi.org/10.5604/16652681.1222096.